- Home
- GHLD vs AUPH Comparison
GHLD vs AUPH Comparison
Compare GHLD & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHLD
- AUPH
- Stock Information
- Founded
- GHLD 1960
- AUPH 1993
- Country
- GHLD United States
- AUPH Canada
- Employees
- GHLD N/A
- AUPH N/A
- Industry
- GHLD Finance: Consumer Services
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- GHLD Finance
- AUPH Health Care
- Exchange
- GHLD Nasdaq
- AUPH Nasdaq
- Market Cap
- GHLD 977.9M
- AUPH 1.1B
- IPO Year
- GHLD 2020
- AUPH 1999
- Fundamental
- Price
- GHLD $19.81
- AUPH $8.86
- Analyst Decision
- GHLD Hold
- AUPH Strong Buy
- Analyst Count
- GHLD 6
- AUPH 2
- Target Price
- GHLD $17.90
- AUPH $11.50
- AVG Volume (30 Days)
- GHLD 147.0K
- AUPH 1.9M
- Earning Date
- GHLD 08-07-2025
- AUPH 07-31-2025
- Dividend Yield
- GHLD 2.52%
- AUPH N/A
- EPS Growth
- GHLD 63.18
- AUPH N/A
- EPS
- GHLD 0.71
- AUPH 0.27
- Revenue
- GHLD $1,131,796,000.00
- AUPH $247,295,000.00
- Revenue This Year
- GHLD $5.64
- AUPH $12.15
- Revenue Next Year
- GHLD $26.37
- AUPH $18.31
- P/E Ratio
- GHLD $27.84
- AUPH $33.04
- Revenue Growth
- GHLD 32.57
- AUPH 29.20
- 52 Week Low
- GHLD $11.21
- AUPH $5.20
- 52 Week High
- GHLD $20.15
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- GHLD 81.04
- AUPH 64.10
- Support Level
- GHLD $19.79
- AUPH $7.36
- Resistance Level
- GHLD $20.02
- AUPH $9.10
- Average True Range (ATR)
- GHLD 0.07
- AUPH 0.44
- MACD
- GHLD -0.14
- AUPH 0.10
- Stochastic Oscillator
- GHLD 30.00
- AUPH 89.53
About GHLD Guild Holdings Company
Guild Holdings Co is a growth-oriented mortgage company. It operates in two segments; The origination segment operates its loan origination business throughout the United States. It is responsible for loan origination, acquisition, and sale activities. This segment is further divided into retail and correspondent channel, and The servicing segment provides a steady stream of cash flow to support the origination segment more importantly it allows for the Company to build long-standing client relationships that drive repeat and referral business back to the origination segment to recapture the client's next mortgage transaction. It is responsible for the servicing activities of all loans in its servicing portfolio. It generates a majority of its revenue from the Origination segment.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.